Characteristic | CENPF expression level | p-value | |
---|---|---|---|
Low (n = 39) | High (n = 40) | ||
Age, n (%) | 0.571 | ||
 ≤ 50 | 22 (27.8%) | 19 (24.1%) |  |
 > 50 | 17 (21.5%) | 21 (26.6%) |  |
Gender, n (%) | 0.196 | ||
 Female | 27 (34.2%) | 21 (26.6%) |  |
 Male | 12 (15.2%) | 19 (24.1%) |  |
Pathologic stage, n (%) |  < 0.001 | ||
 Stage I | 8 (10.4%) | 1 (1.3%) |  |
 Stage II | 25 (32.5%) | 12 (15.6%) |  |
 Stage III | 4 (5.2%) | 12 (15.6%) |  |
 Stage IV | 2 (2.6%) | 13 (16.9%) |  |
Tumor status, n (%) |  < 0.001 | ||
 Tumor free | 28 (36.4%) | 11 (14.3%) |  |
 With tumor | 11 (14.3%) | 27 (35.1%) |  |
New events, n (%) |  < 0.001 | ||
 No | 28 (36.8%) | 11 (14.5%) |  |
 Yes | 11 (14.5%) | 26 (34.2%) |  |
Residual tumora, n (%) |  < 0.001 | ||
 R0 | 38 (54.3%) | 17 (24.3%) |  |
 R1 | 0 (0%) | 6 (8.6%) |  |
 R2 | 0 (0%) | 9 (12.9%) |  |
Laterality, n (%) | 0.436 | ||
 Left | 20 (25.3%) | 25 (31.6%) |  |
 Right | 19 (24.1%) | 15 (19%) |  |
Mitotane therapy, n (%) | 0.259 | ||
 No | 16 (21.3%) | 10 (13.3%) |  |
 Yes | 22 (29.3%) | 27 (36%) |  |
Weiss score, n (%) | 0.002 | ||
 2 | 3 (4.9%) | 0 (0%) |  |
 3 | 9 (14.8%) | 2 (3.3%) |  |
 4 | 7 (11.5%) | 2 (3.3%) |  |
 5 | 5 (8.2%) | 2 (3.3%) |  |
 6 | 3 (4.9%) | 5 (8.2%) |  |
 7 | 5 (8.2%) | 4 (6.6%) |  |
 8 | 1 (1.6%) | 8 (13.1%) |  |
 9 | 0 (0%) | 5 (8.2%) |  |